Metformin versus lifestyle changes in treating women with polycystic ovary syndrome

Gynecological Endocrinology

Volumn 28, Issue 3, 2012, Pages 182-185

  Curi, Daniella D G ^a   Fonseca, Angela Maggio ^a   Marcondes, José Antnio M ^a   Almeida, José Alcione M ^a   Bagnoli, Vicente R ^a   Soares, José Maria ^b   Baracat, Edmund Chada ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

BMI; Lifestyle; Menstrual cycle; Metformin; Polycystic ovary syndrome

Indexed keywords

METFORMIN;

ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; LIFESTYLE MODIFICATION; MENSTRUAL CYCLE; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; WAIST CIRCUMFERENCE;

EID: 84856880680     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.3109/09513590.2011.583957     Document Type: Article

References (24)

1. The Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004;19:41-47.
2. Chang RJ, Nakamura RM, Judd HL, Kaplan SA. Insulin resistance in nonobese patients with polycystic ovarian disease. J Clin Endocrinol Metab 1983;57:356-359. (Pubitemid 13032489)
3. Paradisi G, Steinberg HO, Hempfing A, Cronin J, Hook G, Shepard MK, Baron AD. Polycystic ovary syndrome is associated with endothelial dysfunction. Circulation 2001;103:1410-1415. (Pubitemid 32220633)
4. Barcellos CR, Rocha M P, Hayashida SA, Nery M, Marcondes JA. Prevalence of abnormalities of glucose metabolism in patients with polycystic ovary syndrome. Arq Bras Endocrinol Metabol 2007;51:601-605.
5. Legro RS, Kunselman AR, Dunaif A. Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. Am J Med 2001;111:607-613. (Pubitemid 34088070)
6. Barcellos CR, Rocha M P, Hayashida SA, Mion Junior D, Lage SG, Marcondes JA. Impact of body mass index on blood pressure levels in patients with polycystic ovary syndrome. Arq Bras Endocrinol Metabol 2007;51:1104-1109.
7. Moghetti P, Castello R, Negri C, Tosi F, Perrone F, Caputo M, Zanolin E, Muggeo M. Metformin efects on clinical features, endocrine and metabolic profles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab 2000;85:139-146. (Pubitemid 32268804)
8. Moran LJ, Noakes M, Clifon PM, Tomlinson L, Galletly C, Norman RJ. Dietary composition in restoring reproductive and metabolic physiology in overweight women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003;88:812-819. (Pubitemid 36207827)
9. Huber-Buchholz MM, Carey DG, Norman RJ. Restoration of reproductive potential by lifestyle modifcation in obese polycystic ovary syndrome: role of insulin sensitivity and luteinizing hormone. J Clin Endocrinol Metab 1999;84:1470-1474. (Pubitemid 30644417)
10. Hollmann M, Runnebaum B, Gerhard I. Efects of weight loss on the hormonal profle in obese, infertile women. Hum Reprod 1996;11:1884-1891. (Pubitemid 26381432)
11. Jackson RA, Hawa MI, Jaspan JB, Sim BM, Disilvio L, Featherbe D, Kurtz AB. Mechanism of metformin action in non-insulin-dependent diabetes. Diabetes 1987;36:632-640. (Pubitemid 18024740)
12. Velazquez EM, Mendoza S, Hamer T, Sosa F, Glueck CJ. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metab Clin Exp 1994;43:647-654. (Pubitemid 24145474)
13. Harborne L, Fleming R, Lyall H, Norman J, Sattar N. Descriptive review of the evidence for the use of metformin in polycystic ovary syndrome. Lancet 2003;361:1894-1901. (Pubitemid 36645188)
14. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403. (Pubitemid 34437694)
15. Maciel GA, Soares Júnior JM, Alves da Motta EL, Abi Haidar M, de Lima GR, Baracat EC. Nonobese women with polycystic ovary syndrome respond better than obese women to treatment with metformin. Fertil Steril 2004;81:355-360. (Pubitemid 38223916)
16. Ehrmann DA, Cavaghan MK, Imperial J, Sturis J, Rosenfeld RL, Polonsky KS. Efects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1997;82:524-530. (Pubitemid 27068623)
17. Attia GR, Rainey WE, Carr BR. Metformin directly inhibits androgen production in human thecal cells. Fertil Steril 2001;76:517-524.
18. Pekhlivanov B, Kolarov G, Kavurdzhikova S, Stoikov S. [Determinants of health related quality of life in women with polycystic ovary syndrome]. Akush Ginekol (Sofia) 2006;45:29-34.
19. Hoeger KM, Kochman L, Wixom N, Craig K, Miller RK, Guzick DS. A randomized, 48-week, placebo-controlled trial of intensive lifestyle modifcation and/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study. Fertil Steril 2004;82:421-429. (Pubitemid 39092044)
20. Marcondes JA, Yamashita SA, Maciel GA, Baracat EC, Halpern A. Metformin in normal-weight hirsute women with polycystic ovary syndrome with normal insulin sensitivity. Gynecol Endocrinol 2007;23:273-278. (Pubitemid 46897699)
21. Tang T, Glanville J, Hayden CJ, White D, Barth JH, Balen AH. Combined lifestyle modifcation and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo-controlled, double-blind multicentre study. Hum Reprod 2006;21:80-89. (Pubitemid 41794294)
22. Pascale RW, Wing RR, Butler BA, Mullen M, Bononi P. Efects of a behavioral weight loss program stressing calorie restriction versus calorie plus fat restriction in obese individuals with NIDDM or a family history of diabetes. Diabetes Care 1995;18:1241-1248.
23. Caro JF. Clinical review 26: Insulin resistance in obese and nonobese man. J Clin Endocrinol Metab 1991;73:691-695. (Pubitemid 21921925)
24. Després J P, Lemieux I, Prud'homme D. Treatment of obesity: need to focus on high risk abdominally obese patients. BMJ 2001;322: 716-720. (Pubitemid 32238779)